Loren Data's SAM Daily™

FBO DAILY ISSUE OF JUNE 17, 2011 FBO #3492
SOLICITATION NOTICE

66 -- Affymetrix Exxon Array gene expression chips and reagents

Notice Date

6/15/2011
 

Notice Type

Presolicitation
 

NAICS

334516 — Analytical Laboratory Instrument Manufacturing
 

Contracting Office

Department of Health and Human Services, National Institutes of Health, National Heart, Lung and Blood Institute, Rockledge Dr. Bethesda, MD, Office of Acquisitions, 6701 Rockledge Dr RKL2/6100 MSC 7902, Bethesda, Maryland, 20892-7902
 

ZIP Code

20892-7902
 

Solicitation Number

NHLBI-CSB-(HL)-2011-174-DDC
 

Archive Date

7/13/2011
 

Point of Contact

Deborah - Coulter, Phone: (301) 435-0368
 

E-Mail Address

dc143b@nih.gov
(dc143b@nih.gov)
 

Small Business Set-Aside

N/A
 

Description

THIS IS A NOTICE OF INTENT, NOT A REQUEST FOR A PROPOSAL. A SOLICITATION DOCUMENT WILL NOT BE ISSUED AND PROPOSALS WILL NOT BE REQUESTED. The COAC Services Branch, Office of Acquisitions, DERA, National Heart, Lung, and Blood Institute (NHLBI), NIH, intends to negotiate with Affymetrix, Inc 3420 Central Expwy, Santa Clara, CA 95051, for the following services outline in the statement of work. The North American Industry Classification (NAICS) Code is 334516 and the business size standard is 500 employees. This acquisition is being conducted using Simplified Acquisition Procedures in accordance with FAR Part 13. However, this solicitation is not set aside for small business. Background: Cardiovascular disease (CVD) is the leading cause of death and serious illness in the United States. In 1948, the Framingham Heart Study -- under the direction of the National Heart Institute (now known as the National Heart, Lung, and Blood Institute; NHLBI) -- embarked on an ambitious project in health research. At the time, little was known about the general causes of heart disease and stroke, but the death rate for CVD had been increasing steadily since the beginning of the century and has become an American epidemic. The objective of the Framingham Heart Study was to identify the common factors or characteristics that contribute to CVD by following its development over a long period of time in a large group of participants who had not yet developed overt symptoms of CVD or suffered a heart attack or stroke. The Framingham Heart Study continues to make important scientific contributions by enhancing its research capabilities and capitalizing on its inherent resources. New diagnostic technologies, such as echocardiography (an ultrasound examination of the heart), carotid-artery ultrasound, bone densitometry (for monitoring osteoporosis), and computerized tomography of the coronary arteries, are evaluated and integrated into ongoing protocols. Product: 1. Item Number: 900651, Array Human Exon, 1.0 ST 30/PG, quantity 65 BX 2. Item Number: 900720, RGT, Kit HYB Wash stain 30 RXN, quantity 65 KT I. Contractor Requirements: A. Contractor will provide the gene chips and reagents to analyze 1950 blood samples B. The Contractor will provide the necessary technical support during the sample processing step and the required internal controls for use as a quality control measure. II. Government Responsibilities: A. NHLBI will inspect each chip and reagents to determine if the supplied buffers are adequate for processing 1950 samples. III. Reporting Requirements and Deliverables: A. Prepared cDNA targets from the 1950 samples in NHLBI for concentration and integrity using a spectrophotometer and bioanalyzer. B. Samples that have passed the QC would be hybridized to gene chips for further analysis. Spiked in internal controls supplied by the contractor would be used to determine QC and technical variability The delivery point is the National Institutes of Health, National Heart, Lung, and Blood Institute (NHLBI), Framingham MA. The Government=s anticipated delivery date is twelve months after receipt of purchase order. The sole source determination is based on the fact that Affymetrix is the only known source capable of providing the required supplies, and are the only items that are compatible with government-owned Affymetrix equipment. A change in the product would affect ongoing laboratory research and threaten the investment already made. The notice of intent is not a request for competitive proposals. Only one responsible source and no other supplies or services will satisfy agency requirements. This notice of intent is not a request for competitive proposals. Interested parties may identify their interest and capabilities in response to this synopsis, by June 28, 2011, 7:30am Eastern Standard Time. The determination by the Government not to compete the proposed contract based upon responses to this notice is solely within the discretion of the Government. Information received will normally be considered solely for the purpose of determining whether to conduct future competitive procurement. Inquires to this announcement, referencing synopsis number NHLBI-CSB-(HL)-2011-174-DDC, may be submitted to the National Heart, Lung and Blood Institute, Office of Acquisition, Procurement Branch, 6701 Rockledge Drive, Suite 6042, Bethesda, Maryland 20892-7902, Attention: Deborah Coulter. Response may be submitted electronically to coulterd@nhlbi.nih.gov. Faxes will not be accepted. Responses will only be accepted if dated and signed by an authorized company representative.
 

Web Link

FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/NHLBI/NHLBI-CSB-(HL)-2011-174-DDC/listing.html)
 

Place of Performance

Address: NIH, Framingham, Massachusetts, 01702, United States

Zip Code: 01702
 

Record

SN02474021-W 20110617/110615235256-f3f8ee1cd74c53dcb45b50d7fc909297 (fbodaily.com)
 

Source

FedBizOpps Link to This Notice
(may not be valid after Archive Date)

---

| FSG Index  |  This Issue's Index  |  Today's FBO Daily Index Page |